Imaging the vesicular monoamine transporter.
Imaging the vesicular monoamine transporter.
复制标题
DOI：
--
复制
发表时间：
2001
影响因子：
--
通讯作者：
K. Frey;R. Koeppe;M. Kilbourn
中科院分区：
文献类型：
--
作者：
K. Frey;R. Koeppe;M. Kilbourn
纹状体VMAT2结合位点的定量测量似乎是实验动物模型中黑质纹状体投射完整性的一个很好的替代。重要的是，多巴胺能药物或损伤代偿作用对纹状体VMAT2结合位点的表达水平似乎没有显著影响。使用新型示踪剂(+)11C-DTBZ的PET可以实现对人类VMAT2的高精度和特异性测量。这一方法似乎特别适用于PD严重程度及其进展的客观测量。在寻找帕金森病疗法的疾病改善效果方面，这些措施将是不可或缺的。
Quantitative measures of striatal VMAT2 binding sites appear to represent an excellent surrogate of nigrostriatal projection integrity in experimental animal models. Importantly, there does not appear to be a significant effect of dopaminergic drugs or of lesion compensatory effect on the expressed level of VMAT2 binding sites in the striatum. Highly precise and specific measures of human VMAT2 are possible with PET employing the novel tracer (+)11C-DTBZ. This methodology appears particularly suited to the objective measure of PD severity and of its progression. Such measures will be indispensable in the search for disease-modifying effects of PD therapy.